TrialOphthalmic & physiological optics : the journal of the British College of Ophthalmic Opticians (Optometrists)2026

Negligible Rebound in Myopia Progression Following Cessation of Treatment with 0.01% Atropine for 3 years: Year-4 Results from the CHAMP Phase 3 Clinical Trial.

Karla Zadnik et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.